ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1791

Different Mechanisms Responsible for IVIG Inhibition of Immune Complex Versus TLR Stimulated Interferon-Alpha

Alice Wiedeman1, Fabian Käsermann2, Sylvia Miescher2 and Keith B. Elkon3, 1Department of Immunology, University of Washington, Seattle, WA, 2CSL Behring, Bern, Switzerland, 3Rheumatology Box 356428, University of Washington, Seattle, WA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: interferons, intravenous immunoglobulin (IVIG) and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:   SLE immune complexes (IC) induce IFN-α production by stimulation of TLR7 and 9 in plasmacytoid dendritic cells (pDC).  Serum from normal human donors inhibits IC-induced IFN-α in vitro and both C1q and IgG have been identified as inhibitory serum components. Since pooled IgG (IVIG) is used for therapy of autoimmune diseases and the sialylated subfraction implicated in its mode of action, we addressed how IVIG regulates IFN-α production by pDC.

Methods:   Normal human peripheral blood mononuclear cells (PBMC) or negatively selected pDC were stimulated with SLE IC or the TLR 7 and 9  agonists, Loxoribine (Lox) or CpG-A respectively. IFN-α was quantified in the supernatants by ELISA. Unsorted IVIG or IVIG that had been enriched (SNA+) or depleted (SNA-) of the sialylated subset by a lectin affinity column or digested into Fc or F(ab’)2 fragments were added to stimulated cultures.  SLE IC containing Alexa Fluor 647 labeled SmRNP antigen was allowed to bind to PBMC with or without pretreatment with FcγRII blocking antibody or IVIG Fc, and the binding to pDC quantified by flow cytometry.

Results: IVIG dose-dependently inhibited SLE IC-induced IFN-α (~20%, 50%, and 95% inhibition by treatment with 50, 500, and 5000 μg/mL IVIG, respectively).  Inhibition was Fc-dependent (500 μg/mL IVIG inhibited 50% of IFN-α compared to molar equivalents of F(ab’2), <10%, and Fc, 60%, p<0.01), but was sialylation-independent.  IgG Fc inhibited SmRNP IC binding to pDC (50% of pDC bind IC, which was reduced to 20% with 167 μg/mL Fc, p<0.001).  In contrast, TLR agonist-induced IFN-α was only modestly (10-20%) inhibited by high doses (5000 μg/mL) of IVIG and inhibition was significantly higher by the SNA+ versus SNA- fraction of IVIG (Lox: 90% and 40%, p<0.001; CpG 75% and 0%,  p<0.001, for SNA+ versus SNA-  respectively).  Furthermore, the inhibitory activity was contained in the F(ab’)2 fragment.  The inhibitory activity of sialylated IVIG was not direct on pDC, but required the presence of monocytes (depletion of CD14+ monocytes reduced inhibition by 500 μg/mL SNA+ IVIG after Lox stimulation of IFN-α from 70% to 0%, p<0.05 while depletion of CD19+ B cells or CD56+ NK/NKT cells had no effect). Monocytes produced prostaglandin E2 (PGE2) specifically in response to the sialylated IVIG subset (10-20 ng/mL with SNA+ IVIG compared to undetectable quantities with SNA- IVIG, p<0.05). Furthermore, blockade of PGE2 from the monocyte supernatants reduced inhibitory activity to <10%, and addition of PGE2 blocked IFN-α production.

Conclusion: IVIG Fc directly inhibits production of IFN-α in response to SLE IC by blocking IC binding to FcγRIIa on pDC.  In contrast, the SNA+ subset of IVIG inhibits TLR agonist stimulation of IFN-α by inducing the production of PGE2 by monocytes. Understanding these disparate mechanisms of IVIG inhibition of IFN-α will provide novel methods for immunomodulation and may allow use of smaller amounts of subcomponents of IVIG for therapy.


Disclosure:

A. Wiedeman,

CSL Behring,

2;

F. Käsermann,

CSL Behring,

3;

S. Miescher,

CSL Behring,

3;

K. B. Elkon,

Hoffman La Roche ,

5,

Resolve Therapeutics,

4.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/different-mechanisms-responsible-for-ivig-inhibition-of-immune-complex-versus-tlr-stimulated-interferon-alpha/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology